Positive phase III results for AWcorna mRNA vaccine for prevention of Covid 19.
Results from a multi-center Phase III study in China comparing AWcorna, a mRNA vaccine from Abogen Biosciences, with Sinovac Biotech Ltd.’s older inactivated virus-based vaccine CoronaVac showed AWcorna as a booster induced a 66.59-fold increase against wild-type SARS-CoV-2, and that its protection continued past 14 and 28 days.
The results, published on the pre-peer review site medRxiv, also showed that neutralization antibody titers against the Delta variant increased significantly after a third dose booster either with AWcorna or CoronaVac - but the measurements in the AWcorna groups were 5.1- and 6.5-fold higher than for CoronaVac at 14 and 28 days post-booster.
Safety-wise, a total of eight subjects of the 200 enrolled in the AWcorna group (4%) reported fever, while 7% of the 100 enrolled in the CoronaVac group reported headache and 4% reported fever as the most frequent systemic adverse events. No serious adverse events were reported in either group.
The trial size was small and efficacy needs to be further determined.
See- "Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults"- Xiaoqiang Liu, Yuhua Li, Zhongfang Wang, Shouchun Cao, Weijin Huang, Lin Yuan, Yi-Jiao Huang, Yan Zheng, Jingjing Chen, Bo Ying, Zuoyun Xiang, Jin Shi, Jincun Zhao, Zhen Huang, Cheng-Feng Qin. medRxiv 2022.05.30.22275753; doi: https://doi.org/10.1101/2022.05.30.22275753.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.